<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li J</submitter><funding>Ministry of Science and Technology of the People&amp;apos;s Republic of China</funding><funding>National Natural Science Foundation of China</funding><pagination>2143</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9018847</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>Boron neutron capture therapy (BNCT) is an attractive approach to treat invasive malignant tumours due to binary heavy-particle irradiation, but its clinical applications have been hindered by boron delivery agents with low in vivo stability, poor biocompatibility, and limited application of combinational modalities. Here, we report boronsome, a carboranyl-phosphatidylcholine based liposome for combinational BNCT and chemotherapy. Theoretical simulations and experimental approaches illustrate high stability of boronsome. Then positron emission tomography (PET) imaging with Cu-64 labelled boronsome reveals high-specific tumour accumulation and long retention with a clear irradiation background. In particular, we show the suppression of tumour growth treated with boronsome with neutron irrad</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Boron encapsulated in a liposome can be used for combinational neutron capture therapy.</pubmed_title><pmcid>PMC9018847</pmcid><funding_grant_id>2017YFA0506300</funding_grant_id><funding_grant_id>U1867209</funding_grant_id><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Guo Z</pubmed_authors><pubmed_authors>Sun Q</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Lu C</pubmed_authors><pubmed_authors>Xiao H</pubmed_authors><pubmed_authors>Duan D</pubmed_authors><pubmed_authors>Liu T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Boron encapsulated in a liposome can be used for combinational neutron capture therapy.</name><description>Boron neutron capture therapy (BNCT) is an attractive approach to treat invasive malignant tumours due to binary heavy-particle irradiation, but its clinical applications have been hindered by boron delivery agents with low in vivo stability, poor biocompatibility, and limited application of combinational modalities. Here, we report boronsome, a carboranyl-phosphatidylcholine based liposome for combinational BNCT and chemotherapy. Theoretical simulations and experimental approaches illustrate high stability of boronsome. Then positron emission tomography (PET) imaging with Cu-64 labelled boronsome reveals high-specific tumour accumulation and long retention with a clear irradiation background. In particular, we show the suppression of tumour growth treated with boronsome with neutron irrad</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-22T07:51:37.786Z</modification><creation>2024-11-21T07:08:34.477Z</creation></dates><accession>S-EPMC9018847</accession><cross_references><pubmed>35440126</pubmed><doi>10.1038/s41467-022-29780-w</doi></cross_references></HashMap>